TG Therapeutics | TGTX - Operating Profit


TG Therapeutics reported $50.49M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
AbbVie USD 5.81B 1.23B Dec/2025
Alaunos Therapeutics USD -1.19M 148K Sep/2025
Amgen USD 3.96B 464M Dec/2025
Ardelyx USD 5.1M 431K Dec/2025
Arrowhead Research USD 40.81M 3.3M Dec/2025
Bayer EUR 1.11B 1.65B Dec/2025
Biogen USD 659.6M 192.2M Sep/2025
Corcept Therapeutics USD 4.49M 5.73M Dec/2025
Curis USD -7.88M 4.63M Dec/2025
Gilead Sciences USD 2.96B 551M Dec/2025
Infinity Pharmaceuticals USD -10.12M 1.39M Jun/2023
J&J USD 6.62B 1.03B Mar/2026
Karyopharm Therapeutics USD -17.84M 13.44M Dec/2025
Novartis USD 4.24B 171M Mar/2026
Novavax USD 20.94M 100.32M Dec/2025
PTC Therapeutics USD -81.62M 85.11M Dec/2025
Puma Biotechnology USD 22.08M 24.26M Sep/2024
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Roche Holding CHF 9.56B 3.8B Dec/2025
TG Therapeutics USD 50.49M 21.13M Dec/2025
Verastem USD -41.48M 23.2M Dec/2025
Vertex Pharmaceuticals USD 1.26B 24.5M Dec/2025